Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CALRETICULIN BINDING CONSTRUCTS AND ENGINEERED T CELLS FOR THE TREATMENT OF DISEASES
Document Type and Number:
WIPO Patent Application WO/2019/139987
Kind Code:
A1
Abstract:
Provided herein are nucleic acid constructs, polypeptides and T cells related to antigen binding domains that bind to mutant calreticulin; and methods of use thereof for the treatment of diseases, including cancer.

Inventors:
LOEW ANDREAS (US)
VASH BRIAN EDWARD (US)
Application Number:
US2019/012900
Publication Date:
July 18, 2019
Filing Date:
January 09, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ELSTAR THERAPEUTICS INC (US)
International Classes:
C07K14/47; C07K14/705; C07K16/30
Domestic Patent References:
WO2018144777A22018-08-09
Foreign References:
US20170269092A12017-09-21
US20050090648A12005-04-28
US20170151281A12017-06-01
Other References:
STEIN ET AL.: "A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies", LEUKEMIA, vol. 30, no. 1, 23 July 2015 (2015-07-23), pages 131 - 135, XP055262511, doi:10.1038/leu.2015.192
TEN HACKEN ET AL.: "Calreticulin as a novel B- cell receptor antigen in chronic lymphocytic leukemia", HAEMATOLOGICA, vol. 102, no. 10, 1 October 2017 (2017-10-01), pages e394 - e396, XP055472776
Attorney, Agent or Firm:
ZHANG, MENGMENG (US)
Download PDF: